Merca East entered TCE to develop a new cancer immunotherapy

Recently, Mercator struck a potentially $1 billion strategic partnership with San Diego-based Janux Therapeutics to develop next-generation T-cell joint (TCE) immunotherapy for cancer treatments.
TCE is a new type of immunotherapy that enables T-cells to reorient and collect tumor cells by acting at the same time as tumor target cell antigens and T-cell surface molecules.
, TCE has shown results in a number of hematological cancers, and three CD19-targeted TCE have been approved by the FDA.
but despite TCE's broad anti-cancer prospects, the first two generations of TCE still have unavoidable toxic side effects and immunogenicity.
first generation of TCE triggers a systemic immune response that attacks healthy cells in addition to tumors, potentially life-threatening toxicity, according to Janux's website.
second-generation TCE reduces the initial systemic immune response, over time, activated TCE continues to accumulate leading to immune activation in healthy tissues, etc.
, some pharmaceutical companies are addressing the shortcomings of the first two technologies through a variety of technologies.
Janux, who is now in Merca East's view, has developed a unique TRACTr technology that minimizes the level of the drug in healthy tissue while allowing the drug to maintain a high level of activity in tumor cells for a longer period of time in order to reduce toxic side effects and eradicate tumor cells.
cooperation agreement, Mercadon will obtain a global exclusive license for the products and intellectual property rights developed in this partnership.
but Mercedon will provide research and development funds for the partnership.
in exchange, Janux will receive up to about $500 million per product.
is a big bet for Mercedon, he said.
Because so far, although Janux's TRACTr technology has developed immunotherapy for a variety of solid tumors, including colorectal cancer, gastroesophageal cancer, prostate cancer, non-small cell lung cancer and triple-yin breast cancer, these development pipelines are in the preclinical stage.
, there are also a number of companies in the layout of TCE to develop new immunotherapy.
such as Amjin's Bite immuno-oncology platform, Maverick Therapeutics' COBRA platform, and Roche, Johnson and Johnson, and Yan Jian, have all entered into cooperation agreements with Amunix, a technology platform company.
Lin Yiling Source: Euro Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medical and are not reproduced by any media, website or individual without authorization, and must be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here